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Abstract 32 
Alzheimer’s disease (AD) is a common neurodegenerative disease that starts with a clinically 33 
silent phase of a decade or more during which brain pathologies accumulate predominantly in 34 
the medial temporal lobe but also elsewhere in the brain. Network dysfunction and clinical 35 
symptoms typically appear when senile plaque (amyloid β) and neurofibrillary tangle (tau) 36 
pathologies meet in the brain parenchyma, producing synapse and neuronal loss. For plaque 37 
and tangle pathologies, reliable fluid biomarkers have been developed. These require 38 
sampling of cerebrospinal fluid. Reliable blood tests for plaque and tangle pathologies are 39 
currently lacking, but blood tests for general neurodegeneration have recently been developed. 40 
In AD, plaques and tangles often co-exist with other pathologies, including Lewy bodies, and 41 
to what extent these contribute to symptoms, is currently unknown. There are also important 42 
differential diagnoses that may be possible to distinguish from AD with the aid of biomarkers. 43 
The scope of this review is fluid biomarkers for AD and related pathologies. The purpose is to 44 
provide the reader with an updated account of currently available fluid biomarkers for AD and 45 
clinically relevant differential diagnoses.  46 
 47 
48 
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Introduction 49 
Neurodegenerative dementias constitute a broad category of brain diseases that cause a long 50 
term and often gradual decrease in the ability to think and remember that is great enough to 51 
affect a person’s daily functioning. The most common type of dementia is Alzheimer’s 52 
disease (AD) that makes up 50% to 70% of the cases (98). AD causes a progressive loss of 53 
cognitive abilities with short-term memory impairment being the most typical initial 54 
symptom. However, there are also atypical clinical presentations of AD, e.g., primary 55 
progressive aphasia or posterior cortical atrophy (52), and there are many other dementia-56 
causing diseases that may be important differential diagnoses (70).  57 
 58 
A dementia diagnosis is usually based on the history of the illness, the pattern of cognitive 59 
deficits, with investigations including, e.g., blood work used to rule out other possible (non-60 
cerebral) causes, and imaging both to rule out alternative diagnoses and to provide positive 61 
evidence for a given diagnosis. Specific dementia diagnoses can be made using clinical 62 
criteria that may be supplemented by information from biomarkers (20), but a definite 63 
diagnosis requires autopsy confirmation, based on the fact that each of the degenerative 64 
dementia-causing brain disorders is characterised by more or less distinct neuropathology 65 
(35). A striking feature is that most neurodegenerative dementias show aggregates or 66 
inclusions of specific proteins in the brain extracellular matrix or within neurons or other cell 67 
types of the brain (43). Some researchers have even classified them as “proteopathies” (90).  68 
 69 
Neuropathologically, AD is characterized by neuronal loss in specific brain regions, 70 
intraneuronal neurofibrillary tangles composed of aggregated and often hyperphosphorylated 71 
tau protein, and extracellular neuritic plaques that are deposits of amyloid β (Aβ) peptides, 72 
mainly ending at amino acid 42 (7). Additionally, synapse loss (71) and microglial activation 73 
(89) have been suggested as integral, albeit non-specific, parts of AD pathology. Other 74 
neurodegenerative diseases that may cause AD-like symptoms include frontotemporal 75 
dementia (FTD), where tau and/or TDP-43 may form inclusions, Parkinson’s disease 76 
dementia (PDD) and dementia with Lewy bodies (DLB), where α-synuclein inclusions are 77 
important parts of the pathology, and cerebral small vessel disease, where demyelination of 78 
subcortical brain regions is prominent. There is often also a considerable degree of multi-79 
morbidity in neurodegenerative pathologies, suggesting that pathologically deposited proteins 80 
may interact and are influenced by other factors to promote cognitive decline and other 81 
clinical symptoms. Here, I discuss how biomarkers for different neuropathological changes 82 
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may help inform clinical decision-making and potentially also in the future help to personalize 83 
treatment. Table 1 summarizes replicated fluid biomarker findings in this context.  84 
 85 
In regards to the biomarkers discussed, CSF indicates lumbar CSF collected according to 86 
published standard operating procedures (8); biomarker results derived from ventricular CSF 87 
may be quite different. Further, it is important how samples are collected, processed and 88 
stored, which is also detailed in published protocols (8). Regarding blood-based biomarkers, 89 
the sample matrix (plasma or serum) is specified wherever important. It should also be 90 
mentioned that the potential clinical context of use of the biomarkers discussed below is in a 91 
memory or neurology clinic. It is important to ensure that the patient has not had any acute 92 
CNS disease at least 3-6 months before sampling of the fluid, as for example a stroke, head 93 
trauma or meningitis may affect biomarker concentrations for this time window.  94 
 95 
 96 
Fluid biomarkers for plaque pathology  97 
 98 
CSF 99 
The 42 amino acid isoform of amyloid β (Aβ42) is a major component of senile plaques in 100 
AD (51). It is a breakdown product of unclear physiological function, which is released from 101 
neurons when the type I transmembrane protein amyloid precursor protein (APP) is 102 
metabolized by β- and γ-secretases in synaptic vesicles (APP is metabolized by many cell 103 
types but Aβ42 secretion is by far the highest from neurons and seems to depend on synaptic 104 
activity (14)). Aβ42 can be measured in cerebrospinal fluid (CSF) by antibody-dependent 105 
techniques such as enzyme-linked immunosorbent assay (ELISA), as well as by antibody-106 
independent techniques such as mass spectrometry (44). AD patients have decreased CSF 107 
concentrations of Aβ42, a finding that has been replicated and verified in hundreds of papers 108 
(62). This decrease reflects Aβ42 sequestration in senile plaques in the brain, as evidenced by 109 
both autopsy and in vivo amyloid positron emission tomography (PET) imaging studies (9). 110 
CSF Aβ42 concentration is fully altered already in mild cognitive impairment (MCI) as well 111 
as pre-clinical stages of AD (4, 62). A plaque pathology-associated decrease in CSF Aβ42 112 
concentration is also seen in DLB, another disease characterized by cerebral Aβ aggregation 113 
(1).  114 
 115 
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Blood 116 
It has been much more difficult to establish robust blood biomarkers for plaque pathology. Aβ 117 
proteins can be measured in plasma but the correlation with cerebral β-amyloidosis is absent 118 
or weak (statistically significant but clinically meaningless) (38, 61), and plasma Aβ 119 
concentrations are probably influenced by production in platelets and other extra-cerebral 120 
tissues (103). Pilot data suggest associations of the concentrations of a number of plasma 121 
proteins (e.g., pancreatic polypeptide Y, IgM, chemokine ligand 13, interleukin 17, vascular 122 
cell adhesion protein 1, α2-macroglobulin, apolipoprotein A1 and complement proteins) with 123 
amyloid burden in the brain (12, 97, 100). However, these data should be interpreted with 124 
some caution, as they are derived from multi-marker panels and as a mechanistic 125 
understanding of the associations is currently lacking.  126 
 127 
 128 
Fluid biomarkers for tangle pathology  129 
 130 
CSF 131 
Abnormally phosphorylated and truncated tau proteins are the major components of 132 
neurofibrillary tangles in AD and other so called tauopathies (26). The normal function of tau 133 
is to bind to and stabilize tubulin multimers in neuronal axons. Tangle-marked neurons 134 
release phosphorylated tau that can be measured in CSF by ELISA using antibody 135 
combinations specific against mid-domain phospho-tau epitopes. AD patients have increased 136 
CSF P-tau concentrations (62). CSF P-tau concentration correlates weakly with 137 
neurofibrillary tangle pathology in AD (11, 72); a finding that has been replicated in recent 138 
tau PET imaging studies (13), although the results are less clear than for CSF Aβ42. A major 139 
outstanding research question is why other tauopathies, including some forms of FTD and 140 
progressive supranuclear palsy, do not show P-tau increase, at least not as systematically as 141 
seen in AD. It is possible that these disorders show disease-specific tau phosphorylation, or 142 
that tau is processed or truncated in a way that is not recognized by available assays. Another 143 
potential explanation for the AD specificity of CSF P-tau is if the amount of pathology were 144 
simply greater in AD than in other tauopathies (there is to the best of my knowledge no 145 
published data addressing this hypothesis). CSF P-tau is currently considered the most 146 
specific biomarker for AD; except for herpes encephalitis (25) and superficial CNS siderosis 147 
(36, 42), no other condition shows systematic increase in this biomarker (104).  148 
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 149 
Blood 150 
There are so far no reliable blood biomarkers for neurofibrillary tangle pathology, although 151 
there is an emerging literature on P-tau concentrations in neuronally derived blood exosomes 152 
with contrasting results in regards to association with AD (75, 99).  153 
 154 
 155 
Fluid biomarkers for neuroaxonal degeneration  156 
 157 
CSF 158 
Total tau (T-tau), measured using assays with antibodies against mid-domain tau amino acid 159 
sequences that are not phosphorylated, can be used as a general marker of neuroaxonal 160 
degeneration/injury in AD. AD patients have increased CSF T-tau concentrations (62), and 161 
the higher the increase, the more intense neurodegenerative process (92). However, CSF T-tau 162 
increase is not specific for AD; it is also seen in, e.g., Creutzfeldt-Jakob disease (CJD) (67) 163 
and following stroke (33). Similar results have been reported using CSF visinin-like protein 1 164 
(VLP-1) and fatty acid-binding protein (FABP) that are enriched in neurons, but the 165 
associations with AD are less strong than for CSF T-tau (62). Neuron-specific enolase (NSE) 166 
has been proposed as another candidate biomarker for neuronal loss in AD, but the association 167 
with AD is variable (62) and the results are easily confounded by blood contamination, as 168 
NSE (in contrast to what its name implies) is highly expressed in erythrocytes (66).  169 
 170 
Another CSF biomarker for axonal degeneration is neurofilament light (NF-L), which is a 171 
structural protein in long axons (102). CSF NF-L concentration is increased in AD and 172 
especially so in patients with rapid disease progress (105), but among the dementias, the 173 
highest concentrations are seen in FTD and vascular dementia (VaD) (18, 47, 76); a result that 174 
was recently confirmed in a large retrospective analysis of data from the Swedish Dementia 175 
Registry (77), as well as in atypical parkinsonian disorders (28, 49). As for T-tau, the highest 176 
CSF concentrations of NF-L are seen in CJD (80, 93).  177 
 178 
Blood 179 
CSF assays for T-tau and NF-L were recently developed into ultrasensitive blood tests using 180 
Single molecule array (Simoa) technology (2). Serum or plasma NF-L concentration (either 181 
sample matrix works well) correlates with CSF (correlation coefficients of 0.75 to 0.97) and 182 
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most CSF findings (increased NF-L concentrations in AD, FTD, VaD and atypical 183 
parkinsonian disorders) have been replicated in blood (102). For tau, the situation is 184 
promising but less clear. Firstly, for unknown reasons, tau concentrations are higher in plasma 185 
than in serum (unpublished observation). Secondly, the correlation with the corresponding 186 
CSF concentration is absent (106) or weak (54). Plasma T-tau concentration in AD is 187 
increased but less so than in CSF and there is no detectable increase in the MCI stage of the 188 
disease (54, 106).  189 
 190 
 191 
Fluid biomarkers for synaptic pathology  192 
 193 
CSF 194 
Neurogranin (Ng) is a neural-enriched dendritic protein involved in long-term potentiation of 195 
synapses, particularly so in the hippocampus and basal forebrain. Recently, several 196 
independent studies have shown that the CSF concentration of Ng is increased in AD (31, 41, 197 
45, 46, 85), but not in other neurodegenerative disorders (95), and that the marker predicts 198 
future cognitive decline, brain atrophy and reduction in glucose metabolism in prodromal 199 
disease stages (65, 83). Currently, CSF Ng is the best established CSF biomarker for synapse 200 
loss or dysfunction in AD, although there are other promising markers, including SNAP-25 201 
and Rab3A, in development (5, 10). 202 
 203 
Blood 204 
There are so far no reliable blood biomarkers for synaptic pathology. Ng concentration in 205 
plasma is unchanged in AD (19).  206 
 207 
 208 
Fluid biomarkers for microglial activation 209 
 210 
CSF 211 
Recent reports suggest that the CSF concentration of the secreted ectodomain of triggering 212 
receptor expressed on myeloid cells 2 (Trem2), a molecule that is selectively expressed on 213 
microglia in the CNS (48, 82) and genetically linked to AD (27, 39), is increased in AD in a 214 
disease-specific manner and correlates with CSF T-tau and P-tau (32, 64, 81). These results 215 
are backed by an abundant literature showing increased CSF concentrations of several other 216 
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microglia- and/or macrophage-derived proteins, including chitotriosidase (53, 94), CD14 217 
(101) and YKL-40 (16, 60). Another microglial marker, the C-C chemokine receptor 2, is 218 
expressed on monocytes and one of its ligands, C-C chemokine ligand 2 (CCL2), that can be 219 
produced by microglia, is present at increased concentration in AD CSF (15, 23, 24). Most 220 
studies suggest that these increases are modest with large overlaps between cases and 221 
controls, if compared to the more prominent changes seen in traditional neuroinflammatory 222 
conditions, such as multiple sclerosis (58) or HIV-associated neurocognitive dysfunction (63). 223 
It should also be noted that most proteins mentioned above may also be released from 224 
activated astrocytes; microglial and astrocytic activation are difficult to tease apart using fluid 225 
biomarkers.   226 
 227 
Blood 228 
When measured in plasma or serum, the concentrations of most of the microglia-related 229 
proteins mentioned above are higher than in CSF and probably reflect release from monocytes 230 
and macrophages in peripheral blood rather than CNS-related changes. However, a few 231 
studies suggest a slightly increased plasma concentration of YKL-40 in blood from AD 232 
patients (61).  233 
 234 
 235 
Fluid biomarkers for Lewy body pathology 236 
 237 
CSF 238 
α-Synuclein is the major component of Lewy bodies that are characteristic inclusions of 239 
Parkinson’s disease (PD) and DLB (55) but often also seen in AD (69). In PD and other 240 
synucleinopathies, CSF α-synuclein concentrations are typically lower than in controls (29, 241 
56), whilst in AD and CJD, the concentrations are increased and correlate with T-tau, 242 
suggesting that α-synuclein may also be an non-specific marker of neurodegeneration (56, 59, 243 
79, 84, 96). This has been reported not only in AD and CJD, but also in DLB, where there 244 
may be a competition between aggregation of α-synuclein into Lewy bodies and release of the 245 
protein from degenerating synapses, making the data complex to interpret (40). Currently 246 
available assays for α-synuclein measure total amounts of the protein and not Lewy body-247 
specific isoforms; sensitive and specific assays for the latter would resolve this issue. 248 
However, there are some preliminary reports on increased CSF concentrations of α-synuclein 249 
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oligomers in CSF from PD patients (30, 87) and very recently a sensitive assay that detects 250 
and amplifies the biochemical signal of seeds of α-synuclein oligomers in CSF was published, 251 
giving positive test results in 67 out of 76 PD patients, 10 out of 10 DLB patients and in eight 252 
out of 10 people with MSA (73). Additionally, 12 out of 97 non-PD controls tested positive, 253 
most of whom had AD (73), which might indicate concomitant AD and Lewy body 254 
pathologies.  255 
 256 
Blood 257 
α-Synuclein is highly expressed in red blood cells, a reason why blood contamination during 258 
CSF collection may limit the diagnostic value (3, 34). For the very same reason, blood tests 259 
for α-synuclein pathology in the brain may prove hard to develop. Nevertheless, as peripheral 260 
Lewy body pathology, e.g., in the salivary gland and gut, has been reported in PD (88), blood 261 
or salivary tests for α-synuclein seeds may be something to explore in the future.  262 
 263 
 264 
Fluid biomarkers for TDP-43 pathology 265 
 266 
CSF 267 
Hyperphosphorylated transactive response DNA-binding protein 43 (TDP-43) proteinopathy 268 
accounts for about 50% of FTD patients and has recently been described in aging and in 269 
association with cognitive impairment, especially in the context of AD pathology (37). TDP-270 
43 can be measured in CSF but, unfortunately, most of the protein appears to be blood-271 
derived and its CSF concentration does not reflect TDP-43 pathology and is unaltered in FTD 272 
(22).  273 
 274 
Blood 275 
No reliable blood test for TDP-43 pathology in the CNS exists.  276 
 277 
 278 
 279 
 280 
 281 
 282 
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Fluid biomarkers for blood-brain barrier (BBB) integrity 283 
 284 
CSF 285 
The BBB is the interface between the blood and the brain, regulating the transport of 286 
molecules between the blood and the central nervous system. Its primary function is to 287 
maintain the tightly controlled microenvironment of the brain, which is a critical part in 288 
sustaining a healthy nervous system. The most commonly used measure of BBB function in 289 
clinical laboratory practice is the CSF/serum albumin ratio (86). Proteins cross the BBB at 290 
different rates, depending on their hydrodynamic radii, with passage of larger proteins being 291 
more restricted than that of smaller proteins (21). As albumin is not produced in the CNS, 292 
CSF/serum albumin ratio can be used to assess the integrity of the BBB. A large number of 293 
studies have examined the CSF/serum albumin ratio in AD without finding any clear increase 294 
(61). In contrast, CSF/serum albumin ratio is increased in VaD, suggesting that 295 
cerebrovascular changes are associated with a leakier barrier (78, 91).  296 
 297 
Blood 298 
There are no established blood tests for BBB function, although a number of candidates do 299 
exist. One such protein is occludin, a 65-kDa integral membrane protein that contributes to 300 
tight junction stabilization at barriers (17). However, this protein is not specific to the brain, 301 
but also expressed at high levels in testis, kidney, liver and lung (68), which may explain why 302 
this marker, at least when examined in traumatic brain injury, has failed to produce 303 
interpretable results (74). 304 
 305 
 306 
Increasing the interpretability of fluid biomarker test results by physiological studies in 307 
cell and animal models 308 
When we try to relate concentrations of different proteins in human-derived biofluids to 309 
cellular and/or pathological changes in the CNS, we struggle to know if what we measure is a 310 
breakdown product of dying cells, a cellular reaction to a pathogenic exposure, what cell type 311 
is responsible for the biomarker signal and to what extent the measured change reflects 312 
increased production or decreased clearance. For example, we assume that increased T-tau 313 
concentration in lumbar CSF reflects neuroaxonal breakdown, but are currently failing to give 314 
an answer to why this increase appears rather AD-specific and is absent in most other 315 
neurodegenerative diseases. One potential answer comes from recent studies in disease 316 
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models, where it appears like neurons may respond to Aβ exposure by increasing their 317 
secretion of tau in the absence of frank neuronal death (50). Thus, extracellular T-tau 318 
concentration may be more of an Aβ response marker than a direct marker of neuroaxonal 319 
injury (the temporal disconnect of 5 years or more between onset of amyloid deposition and 320 
CSF T-tau increase could hypothetically be an indicator of differences between an inert build-321 
up and a toxic breakdown/diffusion/leakage phase of Aβ pathology). Similar studies could 322 
potentially shed light on mechanisms by which concentrations of other biomarkers discussed 323 
in this review change in different diseases. Here, recent advances in the generation of 324 
neuronal cell models from stem cells may prove important (6, 57). Such models could easily 325 
be used to test the effects of exposure of neurons to disease-promoting agents and the release 326 
and concentration of biomarkers could be monitored over time and related to cellular markers 327 
of disease.   328 
  329 
 330 
Concluding remarks 331 
Three CSF biomarkers reflecting the core pathological features of AD have been established 332 
and are in common use in clinical neurochemistry laboratories worldwide: T-tau (broadly, but 333 
not exclusively, reflecting neurodegeneration), P-tau (reflecting tau phosphorylation and 334 
tangle formation) and Aβ42 (which inversely correlates with plaque pathology). According to 335 
revised clinical criteria, these markers may help diagnose AD more accurately and open up 336 
the possibility of detecting pre-dementia stages of the disease. A number of additional 337 
biomarkers for other pathologies common in AD and other neurodegenerative proteopathies 338 
do exist. In the future, such biomarker tests could be applied in longitudinal studies to sort out 339 
the temporal appearance of different pathologies during disease progression and assess how 340 
they may interact to produce clinical symptoms. As multi-morbidity appears common, one 341 
potential future scenario is that the biomarkers may be used to sub-classify clinical syndromes 342 
in individual patients according to their pathological signature and, hopefully, individualize 343 
treatment.  344 
 345 
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Table 1. Replicated fluid biomarker candidates that correlate with AD-related 762 
pathologies 763 
Pathology Biomarker Biofluid Direction of Change Context of use 
Plaque pathology Aβ42 CSF Decrease in AD Clinical and 
research 
Neurofibrillary 
tangle pathology 
P-tau CSF Increase in AD Clinical and 
research 
Neurodegeneration T-tau CSF Increase in AD Clinical and 
research 
Plasma Slight increase in AD Research 
NF-L 
 
CSF Increase in AD Clinical and 
research 
Plasma/serum Increase in AD Research 
VLP-1 CSF Increase in AD Research 
FABP CSF Increase in AD Research 
Synaptic 
pathology 
Ng CSF Increase in AD Research 
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 Abbreviations: AD, Alzheimer’s disease; Aβ42, the 42 amino acid form of amyloid β; 764 
P-tau, phosphorylated tau; T-tau, total tau; NF-L, neurofilament light; VLP-1, visinin-765 
like protein 1; FABP, fatty acid-binding protein; Ng, neurogranin; sTREM2, secreted 766 
triggering receptor expressed on myeloid cells 2; CSF, cerebrospinal fluid.  767 
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